Recent changes
Track the most recent changes to the wiki on this page.
2 December 2020
| 12:51 | (User creation log) . . [Lukedliu; Drmnaveed123] | ||
| 12:51 . . User account Drmnaveed123 (talk | contribs) was created | |||
| 09:21 . . User account Lukedliu (talk | contribs) was created |
1 December 2020
| m 20:58 | Pralsetinib (Gavreto) (diff | hist) . . (+492) . . Jwarner (talk | contribs) |
| m 20:54 | Cisplatin (Platinol) (diff | hist) . . (+1,059) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 16:48 | Acute myeloid leukemia (diff | hist) . . (+885) . . Jwarner (talk | contribs) (→Decitabine & Venetoclax {{#subobject:30c499|Regimen=1}}) |
30 November 2020
| m 11:42 | Chlorambucil (Leukeran) (diff | hist) . . (+368) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 11:39 | Carmustine wafer, polifeprosan 20 (Gliadel) (diff | hist) . . (+138) . . Jwarner (talk | contribs) |
| m 11:36 | Carmustine (BCNU) (diff | hist) . . (+1,093) . . Jwarner (talk | contribs) |
| m 11:30 | Busulfan (Myleran) (diff | hist) . . (+193) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| 07:56 | (User creation log) . . User account Rsneha (talk | contribs) was created |
29 November 2020
| m 22:00 | Bleomycin (Blenoxane) (diff | hist) . . (+687) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 21:52 | Asparaginase (Elspar) (diff | hist) . . (+774) . . Jwarner (talk | contribs) (→Also known as) |
| m 21:48 | Aminoglutethimide (Cytadren) (diff | hist) . . (+30) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 21:46 | Vinblastine (Velban) (diff | hist) . . (+72) . . Jwarner (talk | contribs) (→Also known as) |
| m 21:43 | Lomustine (CCNU) (diff | hist) . . (+894) . . Jwarner (talk | contribs) (→Also known as) |
| m 21:37 | Vincristine (Oncovin) (diff | hist) . . (+110) . . Jwarner (talk | contribs) |
| m 21:30 | Ponatinib (Iclusig) (diff | hist) . . (+289) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 21:28 | Pemetrexed (Alimta) (diff | hist) . . (-7) . . Jwarner (talk | contribs) |
| m 21:22 | Osimertinib (Tagrisso) (diff | hist) . . (+31) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| N 21:20 | Contexts (6 changes | history) . . (+475) . . [Jwarner (6×)] | ||
| m | 21:20 (cur | prev) . . (+21) . . Jwarner (talk | contribs) (→Untreated) | ||
| m | 21:18 (cur | prev) . . (+29) . . Jwarner (talk | contribs) (→FDA indication language) | ||
| m | 21:17 (cur | prev) . . (+40) . . Jwarner (talk | contribs) (→Treatment contexts) | ||
| m | 21:09 (cur | prev) . . (+22) . . Jwarner (talk | contribs) (→FDA indication language) | ||
| m | 20:23 (cur | prev) . . (+98) . . Jwarner (talk | contribs) (→Treatment contexts) | ||
| N | 20:22 (cur | prev) . . (+265) . . Jwarner (talk | contribs) (Created page with "''The purpose of this page is to define treatment contexts used in the HemOnc ontology; it is not for other purposes at this time.'' =FDA indication language= ==Metastatic==...") |
| m 21:19 | Nilotinib (Tasigna) (diff | hist) . . (+115) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 21:18 | Neratinib (Nerlynx) (diff | hist) . . (+4) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 21:16 | Mercaptopurine (6-MP) (diff | hist) . . (-123) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 21:12 | Letrozole (Femara) (diff | hist) . . (+55) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 21:08 | Ixabepilone (Ixempra) (diff | hist) . . (+2) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 21:07 | Irinotecan (Camptosar) (diff | hist) . . (-26) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 20:56 | Imatinib (Gleevec) (2 changes | history) . . (+41) . . [Jwarner (2×)] | ||
| m | 20:56 (cur | prev) . . (+35) . . Jwarner (talk | contribs) (→Hypereosinophilic syndrome (HES)) | ||
| m | 20:12 (cur | prev) . . (+6) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 20:54 | Idelalisib (Zydelig) (diff | hist) . . (+328) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 20:50 | Dasatinib (Sprycel) (diff | hist) . . (+164) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 20:26 | Biomarkers (8 changes | history) . . (+643) . . [Jwarner (8×)] | ||
| m | 20:26 (cur | prev) . . (+25) . . Jwarner (talk | contribs) | ||
| m | 20:13 (cur | prev) . . (+48) . . Jwarner (talk | contribs) | ||
| m | 20:05 (cur | prev) . . (+34) . . Jwarner (talk | contribs) | ||
| m | 20:02 (cur | prev) . . (+6) . . Jwarner (talk | contribs) | ||
| m | 19:59 (cur | prev) . . (+176) . . Jwarner (talk | contribs) (→Genes) | ||
| m | 19:59 (cur | prev) . . (+189) . . Jwarner (talk | contribs) (→Proteins) | ||
| m | 19:57 (cur | prev) . . (+71) . . Jwarner (talk | contribs) (→Genes) | ||
| m | 19:53 (cur | prev) . . (+94) . . Jwarner (talk | contribs) (→Genes) |
| m 20:25 | Ramucirumab (Cyramza) (diff | hist) . . (+29) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 20:21 | Regimen classes (diff | hist) . . (-2) . . Jwarner (talk | contribs) |
| m 20:17 | Panitumumab (Vectibix) (diff | hist) . . (+157) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 20:08 | Gemtuzumab ozogamicin (Mylotarg) (2 changes | history) . . (+22) . . [Jwarner (2×)] | ||
| m | 20:08 (cur | prev) . . (-2) . . Jwarner (talk | contribs) (→History of changes in FDA indication) | ||
| m | 20:08 (cur | prev) . . (+24) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
| m 20:06 | Cetuximab (Erbitux) (2 changes | history) . . (+69) . . [Jwarner (2×)] | ||
| m | 20:06 (cur | prev) . . (+32) . . Jwarner (talk | contribs) (→History of changes in FDA indication) | ||
| m | 20:04 (cur | prev) . . (+37) . . Jwarner (talk | contribs) (→History of changes in FDA indication) |
